Transforming promising science into products for patient benefit
Technology Development Fund (TDF) Overview:
The TDF is a seed-stage academic catalyst fund dedicated to translating high-impact academic technologies into the independently-validated, later-stage opportunities sought by industry partners and investors. Technologies funded by TDF range from therapeutics and devices, to diagnostics, vaccines and digital health in both pediatric and adult indications.
Fund promising technologies through two mechanisms: Proof-of-Concept Grant (POCG) – up to $50,000 to validate early-stage projects; Technology Development Grant (TDG) — up to $150,000 to advance validated projects.
Coach clinicians and scientists, through a broad network of advisors, to identify and reach key milestones toward product development.
Partner with our corporate or academic collaborators, and retain contract research organizations (CROs) to leverage technical and product development expertise.
Manage projects and partnerships to maintain focus on development goals.
TDF by the Numbers: 2009-2017
- $8.3M commitment to 76 projects
- $26M in follow-on funding to Boston Children’s Hospital
- 12 licenses and options agreements with commercial partners
- 9 startup companies with $82M in seed funding
- $4.45M in licensing revenue